Neurogene Inc. (NASDAQ:NGNE) Receives Average Rating of “Hold” from Analysts

Shares of Neurogene Inc. (NASDAQ:NGNE) have been given a consensus rating of “Hold” by the seven analysts that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $42.50.

A number of research analysts recently commented on NGNE shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a research report on Wednesday, October 8th. Wall Street Zen downgraded shares of Neurogene from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Finally, HC Wainwright reissued a “buy” rating and set a $70.00 price objective on shares of Neurogene in a research report on Tuesday, January 13th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Neurogene by 17.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock valued at $82,000 after purchasing an additional 1,059 shares in the last quarter. Jennison Associates LLC increased its position in Neurogene by 55.0% during the second quarter. Jennison Associates LLC now owns 167,563 shares of the company’s stock worth $2,505,000 after buying an additional 59,479 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in Neurogene by 43.6% during the second quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock valued at $61,000 after buying an additional 1,232 shares in the last quarter. Schroder Investment Management Group bought a new position in Neurogene during the second quarter valued at about $451,000. Finally, Bank of America Corp DE lifted its position in shares of Neurogene by 81.6% in the second quarter. Bank of America Corp DE now owns 95,401 shares of the company’s stock worth $1,426,000 after buying an additional 42,880 shares during the last quarter. Institutional investors and hedge funds own 52.37% of the company’s stock.

Neurogene Trading Down 2.8%

Shares of NGNE stock opened at $17.55 on Monday. The company has a market capitalization of $271.85 million, a price-to-earnings ratio of -4.27 and a beta of 1.60. Neurogene has a 1-year low of $6.88 and a 1-year high of $37.27. The stock’s fifty day simple moving average is $20.76 and its 200-day simple moving average is $22.12.

Neurogene (NASDAQ:NGNE) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $0.27. On average, sell-side analysts predict that Neurogene will post -4.27 EPS for the current year.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.